Scrip
FDA reviewing safety of Sanofi-Aventis's Lantus insulin
02 July 2009
Malini Guha
Please Login to read the full article.
02 July 2009
Malini Guha
The US
FDA is reviewing many sources of safety data for
Sanofi-Aventis's long-acting (once-daily) insulin analogue Lantus (insulin glargine) to better understand the risk, if any, for cancer. It is discussing with Sanofi-Aventis as to whether any additional studies evaluating the safety and efficacy...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Face-to-face: The FDA, Amgen, and its blockbuster biologic, denosumab
EVENTS
10 February 2010
London, UK
11 February 2010
London, UK
23 February 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
